1.
J Ocul Pharmacol Ther
; 37(5): 249-250, 2021 Jun.
Article
in English
| MEDLINE | ID: covidwho-1458139
Subject(s)
Disruptive Technology/legislation & jurisprudence , Drug Delivery Systems/methods , Drug Development/methods , Drug Industry/legislation & jurisprudence , Biological Products/therapeutic use , Cell- and Tissue-Based Therapy/statistics & numerical data , Contact Lenses , Drug Approval/legislation & jurisprudence , Drugs, Generic , Equipment and Supplies/statistics & numerical data , Genetic Therapy/legislation & jurisprudence , Genetic Therapy/statistics & numerical data , Humans , Japan , United States , United States Food and Drug Administration
2.
CMAJ
; 193(33): E1300-E1302, 2021 08 23.
Article
in English
| MEDLINE | ID: covidwho-1372024
3.
Transfusion
; 60(9): 1905-1909, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-613577
ABSTRACT
New York is at the epicenter of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus. Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYPH) had to make changes to its cellular therapy operations to ensure patient, donor, and staff safety and well-being. In this article, we discuss the process changes we instituted for cellular therapy clinical care, collection, processing, and cryopreservation to cope with the rapidly evolving pandemic.